Cogent Biosciences Inc. (COGT)
NASDAQ: COGT · Pharmaceutical Preparations · Waltham, MA
Our rating: Neutral
Neutral reaffirmed at $31.64, moderate conviction, November 6, 2026.
Breaks if: Turn Cautious if the annualized FCF burn rate rises above $350M in any reported quarter over the next 12 months without a corresponding revenue line emerging, or if the stock declines more than 35% from today's price within that window in the absence of a disclosed recovery catalyst such as new financing or a strategic partnership. Turn Positive if Cogent reports a pivotal-trial success or NDA filing within the next 12 months alongside an explicitly confirmed cash runway of at least eight quarters.
Key figures
| Market value | $4.6B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$408M |
| Free cash flow, last 12 months | −$326M |
| Price to earnings | n/a |
| Free cash flow yield | −7.0% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −99.6% |
| Beta to the S&P 500 | 1.70 |
| Volatility, annualized | 95.9% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-0.59 | −$81M |
| June 30, 2026 | n/a | n/a | $-0.52 | −$78M |
| March 31, 2026 | n/a | n/a | $-0.53 | −$87M |
| December 31, 2025 | n/a | n/a | $-0.61 | −$80M |
| September 30, 2025 | n/a | n/a | $-0.50 | −$64M |
| June 30, 2025 | n/a | n/a | $-0.53 | −$55M |
| March 31, 2025 | n/a | n/a | $-0.52 | −$67M |
| December 31, 2024 | n/a | n/a | $-0.50 | −$61M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 2%, Gemini 1%, Mistral 2%
- Free cash flow for the quarter is above zero: Claude 3%, Gemini 1%, Mistral 1%
14 ledger entries and 36 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.